Ion channel binders and uses thereof
Novel CBD analogs with improved bioavailability and tolerability modulate ion channels to provide effective analgesia, overcoming the limitations of existing pain treatments.
WO2026136622A1PCT designated stage Publication Date: 2026-06-25PRESIDENT & FELLOWS OF HARVARD COLLEGE +1
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- PCT/US2025/060241
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-12-18
- Filing Date
- 2025-12-18
- Publication Date
- 2026-06-25
AI Technical Summary
Technical Problem
Existing treatments for chronic and acute pain, such as those using cannabidiol (CBD), are limited by poor bioavailability, patient tolerability, and potential drug-drug interactions, and there is a need for non-opioid analgesics with minimal abuse liability.
Method used
Development of novel CBD analogs with tunable bioavailability, tolerability, and lipophilicity, targeting ion channels to modulate pain pathways.
Benefits of technology
The novel CBD analogs effectively reduce nociceptor excitability, providing analgesia with minimal side effects and reduced drug interactions, addressing the limitations of existing pain treatments.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure US2025060241_25062026_PF_FP_ABST
Abstract
The present disclosure provides new ion channel binding compounds, as well as compositions, uses, and kits incorporating the same. Further provided are methods of treating diseases and disorders including painful conditions and neurological diseases.
Need to check novelty before this filing date? Find Prior Art